OBJECTIVE: To evaluate the potentially improved therapeutic efficacy and safety of nephrotropic macromolecular prodrugs of glucocorticoids (GCs) for the treatment of lupus nephritis. METHODS: Lupus-prone female (NZB × NZW)F1 mice received monthly injections of N-(2-hydroxypropyl) methacrylamide copolymer-based dexamethasone prodrug (P-Dex) or daily injections of dexamethasone phosphate sodium (Dex; overall dose equivalent to that of P-Dex) for 2 months. During treatment, the mice were monitored for albuminuria, mean arterial pressure, and serum autoantibody levels. Nephritis, renal immune complex levels, and macrophage infiltration were evaluated histologically. Bone quality was analyzed using peripheral dual x-ray absorptiometry and micro-computed tomography. The in vivo distribution of P-Dex was investigated using optical imaging, immunohistochemistry, and fluorescence-activated cell sorting (FACS). The antiinflammatory effect of P-Dex was validated using lipopolysaccharide-activated human proximal tubule epithelial (HK-2) cells. RESULTS: Monthly P-Dex injections completely abolished albuminuria in the (NZB × NZW)F1 mice; this approach was significantly more efficacious than daily Dex treatment. P-Dex treatment did not reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes but did decrease macrophage infiltration, which is a marker of chronic inflammation. Immunohistochemical and FACS analyses revealed that P-Dex was primarily sequestered by proximal tubule epithelial cells, and that it could attenuate the inflammatory response in HK-2 cell culture. In contrast to Dex treatment, P-Dex treatment did not lead to any significant deterioration of bone quality or reduction in the level of total serum IgG. CONCLUSION: Macromolecularization of GCs renders them nephrotropic. Protracted retention, subcellular processing, and activation of GC prodrugs by kidney cells would potentiate nephritis resolution, with a reduced risk of systemic toxicities.
OBJECTIVE: To evaluate the potentially improved therapeutic efficacy and safety of nepn>hrotropic macromolecular prodrugs of glucocorticoids (GCs) for the treatment of lupus nephritis. METHODS: Lupus-prone female (NZB × NZW)F1 mice received monthly injections of N-(2-hydroxypropyl) methacrylamide copolymer-based dexamethasone prodrug (P-Dex) or daily injections of dexamethasone phosphate sodium (Dex; overall dose equivalent to that of P-Dex) for 2 months. During treatment, the mice were monitored for albuminuria, mean arterial pressure, and serum autoantibody levels. Nephritis, renal immune complex levels, and macrophage infiltration were evaluated histologically. Bone quality was analyzed using peripheral dual x-ray absorptiometry and micro-computed tomography. The in vivo distribution of P-Dex was investigated using optical imaging, immunohistochemistry, and fluorescence-activated cell sorting (FACS). The antiinflammatory effect of P-Dex was validated using lipopolysaccharide-activated human proximal tubule epithelial (HK-2) cells. RESULTS: Monthly P-Dex injections completely abolished albuminuria in the (NZB × NZW)F1 mice; this approach was significantly more efficacious than daily Dex treatment. P-Dex treatment did not reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes but did decrease macrophage infiltration, which is a marker of chronic inflammation. Immunohistochemical and FACS analyses revealed that P-Dex was primarily sequestered by proximal tubule epithelial cells, and that it could attenuate the inflammatory response in HK-2 cell culture. In contrast to Dex treatment, P-Dex treatment did not lead to any significant deterioration of bone quality or reduction in the level of total serum IgG. CONCLUSION: Macromolecularization of GCs renders them nephrotropic. Protracted retention, subcellular processing, and activation of GC prodrugs by kidney cells would potentiate nephritis resolution, with a reduced risk of systemic toxicities.
Authors: Ke Ren; P Edward Purdue; Lyndsey Burton; Ling-dong Quan; Edward V Fehringer; Geoffrey M Thiele; Steven R Goldring; Dong Wang Journal: Mol Pharm Date: 2011-04-12 Impact factor: 4.939
Authors: Yijia Zhang; Zhenshan Jia; Hongjiang Yuan; Anand Dusad; Ke Ren; Xin Wei; Edward V Fehringer; P Edward Purdue; Aaron Daluiski; Steven R Goldring; Dong Wang Journal: Pharm Res Date: 2016-05-10 Impact factor: 4.200
Authors: Xin Wei; Fei Li; Gang Zhao; Yashpal Singh Chhonker; Christine Averill; Josselyn Galdamez; P Edward Purdue; Xiaoyan Wang; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Yazen Alnouti; Dong Wang Journal: Mol Pharm Date: 2017-04-05 Impact factor: 4.939
Authors: Gang Zhao; Xin Wei; Jianbo Wu; Derrick D Eichele; Subodh M Lele; Libin Yang; Fan Zhang; Dong Wang Journal: Pharm Res Date: 2019-03-11 Impact factor: 4.200
Authors: Zhenshan Jia; Yijia Zhang; Yen Hsun Chen; Anand Dusad; Hongjiang Yuan; Ke Ren; Fei Li; Edward V Fehringer; P Edward Purdue; Steven R Goldring; Aaron Daluiski; Dong Wang Journal: J Control Release Date: 2014-12-24 Impact factor: 9.776
Authors: Gang Zhao; Rongguo Ren; Xin Wei; Zhenshan Jia; Ningrong Chen; Yuanyuan Sun; Zhifeng Zhao; Subodh M Lele; Haizhen A Zhong; Mary B Goldring; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2021-10-12 Impact factor: 9.776
Authors: Ke Ren; Anand Dusad; Fang Yuan; Hongjiang Yuan; P Edward Purdue; Edward V Fehringer; Kevin L Garvin; Steven R Goldring; Dong Wang Journal: J Control Release Date: 2013-12-08 Impact factor: 9.776
Authors: Xin Wei; Jianbo Wu; Gang Zhao; Josselyn Galdamez; Subodh M Lele; Xiaoyan Wang; Yanzhi Liu; Dhruvkumar M Soni; P Edward Purdue; Ted R Mikuls; Steven R Goldring; Dong Wang Journal: Mol Pharm Date: 2018-07-16 Impact factor: 4.939
Authors: Lingdong Quan; Yijia Zhang; Bart J Crielaard; Anand Dusad; Subodh M Lele; Cristianne J F Rijcken; Josbert M Metselaar; Hana Kostková; Tomáš Etrych; Karel Ulbrich; Fabian Kiessling; Ted R Mikuls; Wim E Hennink; Gert Storm; Twan Lammers; Dong Wang Journal: ACS Nano Date: 2013-12-27 Impact factor: 15.881